Is Elicit profitable?

No official revenue or profitability figures have been disclosed by Elicit as of July 2026. Third-party estimates around $10.5M annual revenue exist but are low-confidence and may blend data from unrelated companies also named Elicit. The startup has raised $31M total across seed and Series A rounds.

Elicit is a privately held, venture-backed Public Benefit Corporation, spun out of nonprofit lab Ought in 2023. It is not owned by a parent company. Investors include Fifty Years, Spark Capital, Footwork, Basis Set Ventures, and Mythos Ventures, following a $22M Series A announced February 26, 2025.

Could AI replace Elicit?

Elicit's core function, automated literature search and extraction, is itself commoditizable by generalist deep-research agents from OpenAI, Google, and Perplexity, which shipped overlapping features by 2025. Elicit's edge is a PRISMA 2020-compliant systematic-review workflow, but its Semantic Scholar-based dataset is available to competitors too.

Is Elicit's accuracy claim trustworthy?

Elicit's May 6, 2026 internal benchmark against 994 Cochrane reviews claimed 95-99% accuracy, but an independent 2025 study by Lau et al. found real-world sensitivity of only 37.9% versus Elicit's claimed 96.9%, exposing a significant credibility gap in its core trust claim.

Who is Elicit's biggest competitor?

Elicit competes directly with Consensus, Semantic Scholar, and Scite.ai in AI literature review, but faces bigger structural threats from OpenAI's ChatGPT Deep Research, Google's Gemini Deep Research, and Perplexity, all of which shipped overlapping deep-research features by 2025, plus incumbents Elsevier and Clarivate.

How much funding has Elicit raised?

Elicit has raised $31M total: a $9M seed round in September 2023 led by Fifty Years with participation from Jeff Dean and Tom Preston-Werner, and a $22M Series A announced February 26, 2025 co-led by Spark Capital and Footwork at a reported valuation of about $100M.

AI companies and labs · United States

Elicit

elicit.com ↗

Elicit builds an AI assistant that helps researchers find, screen, and extract data from academic papers.

Losing its protection

Assessed 21 July 2026 · Evidence as of 21 July 2026

The structural protection is eroding.

On the recordSince 21 July 2026 · Checkable from mid-2026 to July 2026 · Every call on the record Checkpoint: Series B raise on the pharma-pivot story, plus planned API/MCP launch

The call

Elicit has a real regulated-research niche and enterprise pilots, but free generalist AI agents and a credibility gap on its own accuracy claims are closing in fast.

Elicit is a specialized tool that automates systematic literature reviews, the kind required in medicine and regulated industries, and it has built a workflow that follows strict scientific standards (PRISMA 2020) with some real customers in pharma and biotech. The problem is that OpenAI, Google, and Perplexity have all shipped similar deep-research features in their general AI assistants, and they can improve faster because they control the underlying models; plus Elicit relies on the same public database (Semantic Scholar) that competitors can access. The biggest red flag is a recent independent study showing Elicit's real-world accuracy was 37.9 percent, far below its own claimed 96.9 percent, which undermines trust in the exact field where trust is everything. What could change this: if regulated industries (pharma, biotech, medical devices) build legal and compliance requirements around Elicit's auditable, reproducible workflow, that could lock it in where generalist AI tools cannot easily compete, but that barrier has not solidified yet.

Why

AI pressure: OpenAI ChatGPT Deep Research, Google Gemini Deep Research, Perplexity. Generalist deep research agents already read papers and pull structured data, closing on Elicit's core workflow for free. Could AI do the core job? Yes, likely.

Bigger players: Elsevier (Scopus AI) and Clarivate (Web of Science). These own proprietary paper corpora and sell directly into the same libraries and pharma accounts Elicit is chasing. Could a giant copy it? Yes, easily.

What protects it. A PRISMA-compliant, auditable workflow that regulated buyers like pharma and policy bodies can point to for compliance.

What would change this call

Elicit announces or closes a Series B funding round within the next 12 months. Shows investors believe the pharma/regulated-sector pivot is converting into locked-in revenue.
A new independent study re-tests Elicit's search sensitivity against real systematic-review conditions. Would confirm or refute the 37.9% vs. 96.9% accuracy gap found by Lau et al. 2025.
OpenAI, Google, or Perplexity add PRISMA-style audit trails or citation-traceability to their deep research tools. Would show Elicit's specialized systematic-review workflow is being copied by generalist rivals.

Key numbers

$31M total funding raised (2026-06)
53 employees, up from 22 in 2024 (2026-06)
Independent study: 37.9% real sensitivity vs 96.9% claimed (2025)

Named risks

Independent Lau et al. 2025 study found 37.9% real-world sensitivity versus 96.9% internally claimed, undercutting core trust proposition. Severity: high
Underlying dataset relies on Semantic Scholar, a resource freely available to all competitors, limiting data moat. Severity: high
Generalist deep-research agents from OpenAI, Google, and Perplexity ship overlapping features on frontier labs' schedule, not Elicit's. Severity: high
No Series B announced roughly 17 months after February 2025 Series A, raising funding-runway questions. Severity: medium
HQ location and revenue figures are inconsistent across data brokers, indicating weak public data confidence. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
OpenAI (ChatGPT Deep Research)	losing to	Shipped feature-level competitor to Elicit Reports, cited directly in Elicit's own eval, March 2025
Google (Gemini Deep Research)	losing to	Overlapping deep-research feature set shipped by 2025, improving on Google's schedule not Elicit's
Perplexity	contesting	Named as direct competitor to Elicit Reports in Elicit's internal evaluation, March 2025
Elsevier (Scopus AI)	contesting	Owns proprietary dataset and institutional distribution that Elicit lacks, as of 2026
Clarivate (Web of Science)	contesting	Owns proprietary dataset and institutional distribution that Elicit lacks, as of 2026
Consensus	contesting	Direct competitor in AI evidence search over comparable paper dataset, 2026

Questions people ask

Is Elicit profitable?: No official revenue or profitability figures have been disclosed by Elicit as of July 2026. Third-party estimates around $10.5M annual revenue exist but are low-confidence and may blend data from unrelated companies also named Elicit. The startup has raised $31M total across seed and Series A rounds.
Who owns Elicit?: Elicit is a privately held, venture-backed Public Benefit Corporation, spun out of nonprofit lab Ought in 2023. It is not owned by a parent company. Investors include Fifty Years, Spark Capital, Footwork, Basis Set Ventures, and Mythos Ventures, following a $22M Series A announced February 26, 2025.
Could AI replace Elicit?: Elicit's core function, automated literature search and extraction, is itself commoditizable by generalist deep-research agents from OpenAI, Google, and Perplexity, which shipped overlapping features by 2025. Elicit's edge is a PRISMA 2020-compliant systematic-review workflow, but its Semantic Scholar-based dataset is available to competitors too.
Is Elicit's accuracy claim trustworthy?: Elicit's May 6, 2026 internal benchmark against 994 Cochrane reviews claimed 95-99% accuracy, but an independent 2025 study by Lau et al. found real-world sensitivity of only 37.9% versus Elicit's claimed 96.9%, exposing a significant credibility gap in its core trust claim.
Who is Elicit's biggest competitor?: Elicit competes directly with Consensus, Semantic Scholar, and Scite.ai in AI literature review, but faces bigger structural threats from OpenAI's ChatGPT Deep Research, Google's Gemini Deep Research, and Perplexity, all of which shipped overlapping deep-research features by 2025, plus incumbents Elsevier and Clarivate.
How much funding has Elicit raised?: Elicit has raised $31M total: a $9M seed round in September 2023 led by Fifty Years with participation from Jeff Dean and Tom Preston-Werner, and a $22M Series A announced February 26, 2025 co-led by Spark Capital and Footwork at a reported valuation of about $100M.

Timeline

2026-07-15Elicit launched API plus MCP server to power autonomous agent workflows
2026-06-30Elicit upgraded Research Agent to handle gene sequences, omics data, microscopy images
2026-05-06Elicit published internal accuracy benchmark against 994 Cochrane reviews (95-99%)
2026-03-03Elicit launched API preview for programmatic search and report generation
2025-12-19Elicit added Strict Screening and expanded Reports to up to 80 papers
2025-10-23Elicit added keyword search across Elicit, PubMed, and ClinicalTrials.gov
2025-02-26Elicit announced $22M Series A led by Spark Capital and Footwork, ~$100M valuation
2025-02-26Elicit launched Elicit Reports, automated rapid-review reports
2025-02-20Elicit launched Systematic Review workflow with search, screening, extraction
2023-09Elicit raised $9M seed round led by Fifty Years, spinning out of Ought

Revision history

21 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Safe Superintelligence Inc.Mistral AI Cohere